Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more
Scientific production - Institute for Cancer Research
An article by senior scientist Lene Malerød and her co-workers in Kaisa Haglund’s project group shows how the mitotic spindle achieves its correct orientation during cell division.
The article ”Centrosomal ALIX regulates mitotic spindle orientation by modulating astral microtubule dynamics” was published online on June 1 in The EMBO Journal and elucidates a previously unrecognized biological role of the multifunctional adaptor protein ALIX during cell division. Specifically, ALIX is recruited to centrosomes, where it promotes correct mitotic spindle orientation at metaphase during both asymmetric and symmetric cell division, by facilitating the formation of astral microtubules.
In order to stimulate excellent research and draw attention to the hospital's extensive research activity, Oslo University Hospital reward outstanding publications regularly.
Six research groups were awarded for their excellent papers published during the second half-year of 2017 on May 25th in the large auditorium at Ullevål sykehus. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.
The paper entitled “Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins” by Marius S. Eng et al. was a joint academic-industry effort including collaboration with the Ferronel lab at Massachusetts General Hospital/Harvard Medical School, the Rosenblum lab at MD Anderson Cancer Center, the Mælandsmo lab at Oslo University Hospital (OUS), the Imaging Facility at the Institute for Cancer Research (OUS) and PCI Biotech. The manuscript was published in the May issue of Photochemical & Photobiological Sciences (The Royal Society of Chemistry), which is a society-owned journal publishing high quality research on all aspects of photochemistry and photobiology.
Theodossis Theodossiou and Kristian Berg from the Photochemical internalisation (PCI) group at the Department of Radiation Biology at the Institute for Cancer Research have been funded by the Future and Emerging Technology (FET) program under the Excellent Science section of the Horizon 2020. The FET program funded 11 projects out of 820 grant applications (1,4 % success rate) and the proposal by Theodossiou and Berg was rated as number 6. The project is designed to develop treatment of aggressive brain tumors such as glioblastoma multiforme (GBM). The major national newspaper VG recently (May 3rd) published a feature article about the supported project, entitled "Pioneering Norwegian technology: aiming to kill aggressive brain tumors by producing light in the brain."